Submit an Article
Online ISSN: 1945-4589
Impact Journals, LLC. is the publisher of Aging: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
Learn about our FREE Post-Publication Promotion Services

Epigenetic Aging and DNA-Methylation as Tumor Markers for Breast Cancer

01-20-2025

“Our study contributes to the development of a DNAm biomarker that integrates conventional BC risk factors to better reflect the risk for BC subtypes, promoting epigenetically targeted preventive interventions tailored to aged individuals with high risk.”

Listen to an audio version of this press release

BUFFALO, NY- January 20, 2025 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) on December 5, 2024, Volume 16, Issue 22, titled “DNA-methylation age and accelerated epigenetic aging in blood as a tumor marker for predicting breast cancer susceptibility.”

Researchers Su Yon Jung, Herbert Yu, Youping Deng, and Matteo Pellegrini from the University of California, Los Angeles and University of Hawaii Cancer Center have found that a simple blood test could help predict breast cancer (BC) risk in older women. Their study focuses on epigenetic aging, a process that reflects how fast the body’s cells age based on DNA methylation changes (DNAm).

Breast cancer is one of the most common cancers worldwide, with the risk increasing significantly after menopause. The researchers analyzed blood samples from postmenopausal, non-Hispanic white women. They discovered that those with an “older” biological age had a significantly higher risk of being diagnosed with breast cancer. The risk was even greater in women who had their ovaries removed before natural menopause, likely due to reduced estrogen levels, a hormone that plays a key role in aging and breast health.

“Of note, in women with bilateral oophorectomy before natural menopause experiencing shorter lifetime estrogen exposure than those with natural menopause, epigenetic age accel substantially influenced BC development, independent of obesity status and exogeneous estrogen use.”

The study also found that lifestyle factors influence epigenetic aging and breast cancer risk. Women with obesity experienced faster biological aging, which increased their risk of developing cancer. Meanwhile, hormone replacement therapy had varying effects depending on the type and duration of treatment.

Early detection of breast cancer is crucial for effective treatment and survival. Traditional risk assessments—such as age, family history, and lifestyle habits—may not provide the full picture. This study suggests that adding a blood test to measure biological aging could help clinicians identify high-risk women earlier and offer personalized prevention strategies.

With further research, this blood test could become a routine screening tool in women’s health check-ups. It may empower women to take proactive steps to reduce their breast cancer risk through healthy lifestyle choices, including maintaining a balanced diet, staying physically active, and considering appropriate hormone therapies under medical supervision.

In conclusion, further studies are needed to validate these findings and explore their applicability to a broader population of women. However, this research presents a promising, non-invasive, and cost-effective approach to predicting breast cancer risk. 

Read the full paper: DOI: https://doi.org/10.18632/aging.206169

Corresponding author: Su Yon Jung, sjung@sonnet.ucla.edu

Keywords: aging, DNA methylation-based marker of aging, pre-diagnostic DNA, breast cancer, tumorigenesis, postmenopausal women

Click here to sign up for free Altmetric alerts about this article.

About Aging-US:

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Please visit our website at www.Aging-US.com and connect with us:

For media inquiries, please contact media@impactjournals.com.